Genetic Engineering & Biotechnology NewsVol. 32, No. 4 Point of ViewHow Is the FDA Really Doing?Bogus “Study” Gives Agency More Credit Than Is DueHenry I. MillerHenry I. MillerHenry I. Miller, M.D. (E-mail Address: henry.miller@stanford.edu), is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University's Hoover Institution and a fellow at the Competitive Enterprise Institute. He was the founding director of the FDA's Office of Biotechnology.Search for more papers by this authorPublished Online:15 Feb 2012https://doi.org/10.1089/gen.32.4.01AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byQuantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment15 April 2016 | Evolutionary Applications, Vol. 9, No. 5Low-dose paroxetine exposure causes lifetime declines in male mouse body weight, reproduction and competitive ability as measured by the novel organismal performance assayNeurotoxicology and Teratology, Vol. 47 Volume 32Issue 4Feb 2012 Information© 2012 by GEN PublishingTo cite this article:Henry I. Miller.How Is the FDA Really Doing?.Genetic Engineering & Biotechnology News.Feb 2012.6-8.http://doi.org/10.1089/gen.32.4.01Published in Volume: 32 Issue 4: February 15, 2012PDF download